Molecular Biology

S.J. Baker, S. Markowitz, E.R. Fearon, J.K.V. Willson, B. Vogelstein, "Suppression of human colorectal carcinoma cell growth by wild- type p53,"Science, 249:912-15, 1990. S.J. Baker, A.C. Preisinger, J.M. Jessup, et al., "p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis," Cancer Research, 50:7717-22, 1990. Bert Vogelstein (Johns Hopkins Oncology Center, Baltimore, Md.): "Cancer represents not one disease but hundreds. Accordingly,

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

S.J. Baker, S. Markowitz, E.R. Fearon, J.K.V. Willson, B. Vogelstein, "Suppression of human colorectal carcinoma cell growth by wild- type p53,"Science, 249:912-15, 1990. S.J. Baker, A.C. Preisinger, J.M. Jessup, et al., "p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis," Cancer Research, 50:7717-22, 1990.

Bert Vogelstein (Johns Hopkins Oncology Center, Baltimore, Md.): "Cancer represents not one disease but hundreds. Accordingly, cancer researchers have long tried to find common threads that link these diseases together, providing generalized insights into the processes underlying human neoplasia. The p53 gene appears to be one such thread. Research over the last three years has shown that p53 is mutated in diverse forms of human tumors. The papers noted above provide some basic information about the nature and effects of these mutations.

"The data suggest that the normal p53 gene can inhibit the growth of human cancer cells and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies